definiens: means ( A ) all Compounds known as of the effective date of theapplicable CDI Cessation Notice and all other molecules within the libraries of CTLA-4 Variants existing on the effective dateof the applicable CDI Cessation Notice ( provided, however, that all Clinical Candidates which are, as of the effective date ofthe applicable CDI Cessation Notice, in clinical trials or being Commercialized for Exclusive Indications, shall be excludedfrom the definition of for so long as [COMPANY] retains its exclusive license hereunder with respect tosuch Clinical Candidates for the Exclusive Indications ( such Clinical Candidates being the ) ), and(B ) molecules ( other than any Excluded Compounds ) in new CLTA-4 Variant libraries created through Shuffling after theeffective date of the applicable CDI Cessation Notice ( provided, however, that [COMPANY] - Selected New Compounds, as definedbelow, shall not be for so long as [COMPANY] retains its exclusive license hereunder with respect to suchClinical Candidates for the Exclusive Indications ) ; ( iv ) For so long as [COMPANY] retains its exclusive license hereunder with respect to Clinical Candidates for theExclusive Indications, [COMPANY] shall not Develop or Commercialize for Co - Development Indications ( or license ThirdParties to Develop or Commercialize for Co - Development Indications ) any Excluded Compounds or any [COMPANY] - SelectedNew Compound ( as defined below ) ; ( v ) In the event that following partial termination of this Agreement pursuant to this Section 13.4.2 Maxygencreates one or more new CLTA-4 Variant libraries using Shuffling during the period while [COMPANY] retains its exclusive licensehereunder with respect to Products for Exclusive Indications ( ), then [COMPANY] shall provide [COMPANY] allmaterial technical and scientific information and data obtained or reviewed by [COMPANY] and material to [COMPANY] ’s selectionas set forth below, and [COMPANY] may select from such CTLA-4 Variants two ( 2 ) andMaxygen may select two ( 2 ) as follows : ( A ) within [ * * * * ] days after receipt of theinformation described above in this Section 13.4.2(e)(v ) regarding the CTLA-4 Variants in the New Libraries, [COMPANY] mayselect in its discretion, by written notice to [COMPANY], one CTLA-4 Variant * Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission